文献速递眼底病与葡萄膜炎

半剂量光动力疗法与高密度微脉冲激光治疗慢性中心性浆液性脉络膜视网膜病变的PLACE试验

Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.
PubMed 文献 · Ophthalmology · 2018-06-14

PLACE试验为开放标签多中心随机对照研究,纳入179例慢性中心性浆液性脉络膜视网膜病变患者,比较半剂量光动力疗法与高密度微脉冲激光的疗效与安全性。结果显示半剂量光动力疗法在促进视网膜下液完全吸收和改善视功能方面均优于微脉冲激光。

要点

  • 首次随访时半剂量光动力疗法组视网膜下液完全吸收率51.2%,微脉冲激光组13.8%(P < 0.001)。
  • 末次随访时半剂量光动力疗法组无视网膜下液比例67.2%,微脉冲激光组28.8%(P < 0.001)。
  • 半剂量光动力疗法组最佳矫正视力提高(+4.60±6.62 ETDRS字母)优于微脉冲激光组(+1.39±8.99 ETDRS字母),P = 0.011。

核心结论

  • 半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变优于高密度微脉冲激光,表现为视网膜下液完全吸收的患者比例更高且视功能改善更显著。

研究设计与样本

  • 开放标签、多中心、随机对照临床试验,纳入179例经临床特征和多模式影像学检查确认的慢性中心性浆液性脉络膜视网膜病变患者,按1:1随机分为半剂量光动力疗法组89例和高密度微脉冲激光组90例。

主要发现

  • 首次评估(治疗后6至8周)时视网膜下液完全吸收率半剂量光动力疗法组为51.2%,高密度微脉冲激光组为13.8%(P < 0.001)。
  • 末次评估(治疗后7至8个月)时无视网膜下液比例半剂量光动力疗法组为67.2%,高密度微脉冲激光组为28.8%(P < 0.001)。
  • 首次评估时最佳矫正视力提高半剂量光动力疗法组为+4.60±6.62 ETDRS字母,高密度微脉冲激光组为+1.39±8.99 ETDRS字母(P = 0.011)。
  • 首次评估时微视野视网膜敏感度提高半剂量光动力疗法组为+2.01±3.04 dB,高密度微脉冲激光组为+0.92±3.65 dB(P = 0.046)。
  • 视觉相关生活质量评分改善两组相似,半剂量光动力疗法组为+2.87±8.35,高密度微脉冲激光组为+2.56±7.36(P = 0.800)。

关键数值与推荐

  • 主要终点为治疗后6至8周首次评估时视网膜下液完全消失。
  • 次要终点包括末次评估时视网膜下液完全消失、最佳矫正视力(ETDRS字母)变化、微视野视网膜敏感度变化及视觉相关生活质量问卷评分变化。
  • 视网膜下液持续存在的患者重复接受相同治疗。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the anatomic and functional efficacy and safety of half-dose photodynamic therapy (PDT) versus high-density subthreshold micropulse laser (HSML) treatment in patients with chronic central serous chorioretinopathy (cCSC). DESIGN: Open-label, multicenter, randomized controlled clinical trial. PARTICIPANTS: Patients with cCSC whose disease had to be confirmed by both clinical characteristics and findings on multimodal imaging. METHODS: Eligible patients were randomized in a 1:1 allocation ratio. Treatment was evaluated during a follow-up visit, and the same treatment was repeated in patients who still demonstrated subretinal fluid (SRF). MAIN OUTCOME MEASURES: The primary end point was the complete disappearance of SRF at the first evaluation visit at 6 to 8 weeks after treatment. As a secondary outcome measure, we assessed this anatomic result at the final evaluation visit at 7 to 8 months after treatment. Other secondary outcomes covered functional improvement and included change in best-corrected visual acuity (BCVA; measured in Early Treatment Diabetic Retinopathy Study [ETDRS] letters), retinal sensitivity (measured using microperimetry), and vision-related quality of life using a validated questionnaire. RESULTS: Between November 2013 and September 2016, 179 patients were included: 89 patients were assigned randomly to half-dose PDT, and 90 were assigned randomly to HSML treatment. At their first evaluation visit, SRF had resolved in 51.2% and 13.8% of patients, respectively (P < 0.001). At their final evaluation visit, a significantly higher percentage of PDT-treated patients demonstrated no SRF (67.2% vs. 28.8%; P < 0.001). Moreover, at the first evaluation visit, the PDT-treated patients showed a significantly higher increase in BCVA (+4.60±6.62 ETDRS letters vs. +1.39±8.99 ETDRS letters; P = 0.011), and a significantly higher increase in retinal sensitivity on microperimetry (+2.01±3.04 dB vs. +0.92±3.65 dB; P = 0.046); however, the improvement in vision-related quality of life was similar (score of +2.87±8.35 vs. +2.56±7.36, respectively; P = 0.800). CONCLUSIONS: Half-dose PDT is superior to HSML for treating cCSC, leading to a significantly higher proportion of patients with complete resolution of SRF and functional improvement.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. van Dijk EHC, Fauser S, Breukink MB, et al. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology. 2018. PMID: 29776672. doi:10.1016/j.ophtha.2018.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。